CorMedix Inc. — Director's Dealing 2012

Mar 22, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CorMedix Inc. (CRMD)
CIK: 0001410098
Period of Report: 2012-03-20

Reporting Person: LENZ BRIAN (SEE REMARKS)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-03-20	Stock Option (Right to Buy)	$0.49	A	180000	Acquired	2022-03-20	Common Stock, $0.001 par value per share (180000)	Direct

Footnotes

F1: The options vest according to the following schedule: (i) 25% on the date of grant, (ii) 25% upon the closing of a financing by the Company with gross proceeds in excess of $1.5 million, including the issuance of equity, debt or any combination thereof, (iii) 25% upon CE Mark approval for CRMD003 (Neutrolin(R)), and (iv) 25% upon the launch of Neutrolin(R) in Europe; provided, however, that each of the events described in clauses (ii), (iii) and (iv) occur on or before December 31, 2012.